intrommune_icon_500x500.png
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
July 22, 2021 16:57 ET | Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics to Present at BIO Digital 2021
June 17, 2021 09:11 ET | Intrommune Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Chief Operating Officer
March 25, 2021 09:10 ET | Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
intrommune_icon_500x500.png
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
March 12, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
intrommune_icon_500x500.png
Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report
February 23, 2021 12:00 ET | Intrommune Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...
intrommune_icon_500x500.png
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
February 04, 2021 09:13 ET | Intrommune Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune Logo Only - 250k.jpg
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”
January 07, 2021 17:35 ET | Intrommune Therapeutics
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
October 20, 2020 10:00 ET | Intrommune Therapeutics
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal,...
Intrommune Logo Only - 250k.jpg
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies
October 08, 2020 09:50 ET | Intrommune Therapeutics
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies. The article,...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Featured at Upcoming Investor Conferences
October 05, 2020 14:55 ET | Intrommune Therapeutics
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...